Images
- The MAF Test®, developed by IRB Barcelona–ICREA spin-off Inbiomotion, is now available across the US through NeoGenomics Laboratories.
- The test helps identify patients who may benefit from adjuvant bisphosphonate therapy, while avoiding unnecessary treatment for others.
- Its clinical utility is supported by landmark trials and its inclusion in the 2025 SEOM-GEICAM-SOLTI clinical guidelines.
The MAF Test® is now available across the US through NeoGenomics Laboratories, a cancer diagnostics company specializing in cancer genetics testing and information services. The test, developed following a scientific discovery by Dr. Roger Gomis’ lab, could potentially benefit an estimated 258,000 newly diagnosed early-stage breast cancer patients each year in the country.
This tissue-based diagnostic helps oncologists predict recurrence and survival rates. It identifies patients with MAF-negative tumours (80% of cases), who may benefit from adjuvant bisphosphonate therapy, while helping spare patients with MAF-positive tumours from ineffective or potentially harmful overtreatment.
The clinical utility and underlying biological mechanism of the MAF biomarker have been validated in landmark clinical trials and published in leading journals, including The Lancet Oncology, the Journal of the National Cancer Institute and Nature Cell Biology. The test is also included in the 2025 SEOM-GEICAM-SOLTI clinical guidelines.
Precision oncology rooted in IRB Barcelona research
The MAF Test® is a tissue-based diagnostic kit that detects MAF gene amplification in primary breast tumours. It stems directly from research conducted at IRB Barcelona by Dr. Roger Gomis, who identified the MAF gene as a biomarker for predicting bone metastasis in breast cancer.
The test's clinical value has been demonstrated in data from the AZURE and NSABP-B34 trials, each involving more than 3,000 patients. Results published in The Lancet Oncology (2017) and the Journal of the National Cancer Institute (2021) showed that 80% of breast cancer patients have MAF-negative tumours. In this group, treatment with clodronate or zoledronic acid increased disease-free survival by 14.3% and reduced the relative risk of death by 21.4%. By contrast, MAF-positive patients showed no benefit or a worse prognosis, regardless of menopausal status.
These findings support the use of the MAF Test® to identify patients most likely to benefit from adjuvant bisphosphonate therapy and help prevent overtreatment.
Entering the US market and expanding global reach
The US launch marks another milestone in Inbiomotion's international expansion. The test is already available in Spain, Portugal, Italy, the United Kingdom, Ireland, South Korea and Sub-Saharan Africa.
"We are very pleased that oncologists and their patients in the United States now have access to the MAF Test® through NeoGenomics, a frontrunner in innovative oncology testing," said Joël Jean-Mairet, PhD, Executive Chairperson of Inbiomotion. "U.S. availability marks a major step in making precision medicine a reality for early-stage breast cancer patients worldwide. By helping physicians identify which patients are more likely to benefit from specific therapies, we aim to improve outcomes and reduce unnecessary treatments."
"We believe that expanding access to the MAF Test® in the United States will have a tangible impact on patient care," added Ralf van den Berg, Inbiomotion's Chief Operating Officer. "It supports the movement toward more precise, biology-driven treatment strategies in breast cancer, benefiting both patients and healthcare systems. The results of AZURE and NSABP-B34 studies show that the MAF Test® could identify 8 out of 10 of the 258,000 early-stage breast cancer patients diagnosed each year who may have improved outcomes."
About Inbiomotion
Inbiomotion is a spin-off of IRB Barcelona and ICREA, founded in 2011 by Prof. Dr. Roger Gomis following the identification of the MAF gene as a biomarker for predicting bone metastasis in breast cancer.
The company has developed the MAF Test®, a diagnostic kit based on the detection of MAF gene amplification, to promote precision medicine and improve breast cancer treatment. Inbiomotion holds more than 200 patents and patent applications covering its proprietary MAF Test® FISH and the use of bisphosphonates in the adjuvant treatment of early-stage breast cancer.
The company's main investors are Ysios Capital, Caixa Capital Risc, Alta Life Sciences and the Vila Casas Foundation.
For more information, visit www.inbiomotion.com.
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).